Atlas Trials

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

Clinical trial NCT04391283 · UNKNOWN

Trial details

NCT number
NCT04391283
Sponsor
First Affiliated Hospital of Zhejiang University
Status
UNKNOWN
Study type
OBSERVATIONAL
Carcinoma, Non-Small-Cell Lung
Start date
2020-07-27
Primary completion
2022-04-26
Enrollment
500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.